These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome. Bogan RK Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821 [TBL] [Abstract][Full Text] [Related]
5. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Boroojerdi B; Wolff HM; Braun M; Scheller DK Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503 [TBL] [Abstract][Full Text] [Related]
6. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome. Garnock-Jones KP Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269 [TBL] [Abstract][Full Text] [Related]
7. Rotigotine and restless legs syndrome: new indication. The worst dopamine agonist. Just as unsatisfactory; defective design. Prescrire Int; 2009 Oct; 18(103):197. PubMed ID: 19882782 [No Abstract] [Full Text] [Related]
8. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Saletu B; Trenkwalder C; Sommerville KW; Schollmayer E; Kohnen R; Stiasny-Kolster K; Sleep Med; 2008 Mar; 9(3):228-39. PubMed ID: 17553743 [TBL] [Abstract][Full Text] [Related]
9. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100 [TBL] [Abstract][Full Text] [Related]
10. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K; Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany. Stiasny-Kolster K; Berg D; Hofmann WE; Berkels R; Grieger F; Lauterbach T; Schollmayer E; Bachmann CG Sleep Med; 2013 Jun; 14(6):475-81. PubMed ID: 23668924 [TBL] [Abstract][Full Text] [Related]
12. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Kenney C; Jankovic J Expert Opin Pharmacother; 2007 Jun; 8(9):1329-35. PubMed ID: 17563266 [TBL] [Abstract][Full Text] [Related]
13. [Transdermal Rotigotine in the treatment of restless legs patients who develop augmentation of symptoms]. Miranda C M Rev Med Chil; 2013 Mar; 141(3):407-8. PubMed ID: 23900336 [No Abstract] [Full Text] [Related]
14. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Beneš H; García-Borreguero D; Ferini-Strambi L; Schollmayer E; Fichtner A; Kohnen R Sleep Med; 2012 Jun; 13(6):589-97. PubMed ID: 22503658 [TBL] [Abstract][Full Text] [Related]
15. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome. Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951 [TBL] [Abstract][Full Text] [Related]
16. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370 [TBL] [Abstract][Full Text] [Related]
17. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. Högl B; Oertel WH; Stiasny-Kolster K; Geisler P; Beneš H; García-Borreguero D; Trenkwalder C; Poewe W; Schollmayer E; Kohnen R BMC Neurol; 2010 Sep; 10():86. PubMed ID: 20920156 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years. Dohin E; Högl B; Ferini-Strambi L; Schollmayer E; Fichtner A; Bauer L; García-Borreguero D Expert Opin Pharmacother; 2013 Jan; 14(1):15-25. PubMed ID: 23256574 [TBL] [Abstract][Full Text] [Related]
19. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Stiasny-Kolster K; Kohnen R; Schollmayer E; Möller JC; Oertel WH; Mov Disord; 2004 Dec; 19(12):1432-8. PubMed ID: 15390055 [TBL] [Abstract][Full Text] [Related]
20. Rotigotine for restless legs syndrome. Davies S Drugs Today (Barc); 2009 Sep; 45(9):663-8. PubMed ID: 19956807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]